PharmacovigilanceOfficial
FDA creates CBER Safety Council to oversee postmarket safety of biologics
🇺🇸 FDA CBER · Thu 19 Nov 2026
The new body replaces CBER's Safety Working Group, sits apart from the product offices and reports directly to the Center Director, effective 19 November 2026.
The US Food and Drug Administration has established the CBER Safety Council (CSC), a governance body within the Center for Biologics Evaluation and Research. It will oversee postmarket safety for CBER-regulated products, including cell and gene therapies, vaccines, and blood and blood products. The council took effect on 19 November 2026 and evolves from CBER's long-standing Safety Working Group.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Article written by VigiEye from the official source (FDA CBER). AI-assisted; check the source before acting.
More Pharmacovigilance
All →
FDA early alert: Heraeus Medevio recalls vascular guidewires over hydrophilic coating clumping risk
🇺🇸 FDA MedWatch · Fri 20 Nov 2026
EMA publishes PSUSA outcome for ibuprofen medicines, concluding with a variation
🇪🇺 EMA · Fri 20 Nov 2026
EMA publishes PSUSA outcome for nationally authorised split-virion inactivated influenza vaccines, recommending a variation
🇪🇺 EMA · Fri 20 Nov 2026
CMS proposes Medicare Advantage rule to ease market entry and widen beneficiary choice
🇺🇸 CMS · Fri 20 Nov 2026
CMS issues proposed rule on 2028 Medicare Advantage and Part D changes
🇺🇸 CMS · Fri 20 Nov 2026
FDA warns Florida clinical investigator over consent failings in INSTI HIV self-test study
🇺🇸 FDA CBER · Fri 20 Nov 2026